Whirlwind Week for Developments on Medical Marijuana, Inc. (OTCMKTS: MJNA)


The last time we touched upon Medical Marijuana, Inc. (OTCMKTS: MJNA) here on Street Register, we posited that the company could be due to undergo some growing pains. At the time, comments from White House Press Secretary Sean Spicer sent shockwaves through the domestic cannabis space. He suggested an imminent federal crackdown on recreational marijuana that caused trouble for even the medical marijuana stocks like MJNA.

More recently, Attorney General Jeff Sessions suggested that the Department of Justice budget wouldn’t accommodate such a federal crackdown on pot, followed by a period of reinvigoration for many cannabis plays. MJNA was among those to enjoy a boost on the charts, aided by a rapid-fire series of press releases relaying pertinent updates.

According to our promise to keep our readers up-to-date on the happenings at companies we cover, there are a number of things to relay regarding Medical Marijuana, Inc. (OTCMKTS: MJNA) so we’re going to outline the various updates that have been provided since our last article on the company. Shortly thereafter, its subsidiary HempMeds® Mexico garnered national news headlines across Mexico for the positive results of a recent study conducted by renowned Mexican physician Dr. Saul Garza Morales on the effects of its RSHO-X™ product in treating children with severe epilepsy. HempMeds® Mexico was the first company to receive government import permits for its cannabidiol (CBD) oil product Real Scientific Hemp Oil-X™ (RSHO-X™) via the Mexican Health Department COFEPRIS. (Source: Canada Presswire)

The study, conducted by Mexican pediatric neurologist Dr. Garza, included 39 patients with Lennox-Gastaut syndrome, a severe form of pediatric epilepsy that typically develops before the age of four. Of those 39 patients, which took up to 5-7mg CBD/kg progressive doses of RSHO-X™ 5000MG, 84% experienced reduction in motor seizures; 53% reported better than a 75% reduction in seizures; and 7 reported a complete elimination of all seizures over a 4-month period, with zero reported side effects. In addition, the study showed twice the efficacy in seizure reduction as per GW Pharmaceuticals’ Epidiolex – with ZERO adverse side effects. In contrast, 79% of children in GW’s Epidiolex study reported suffering adverse effects and 30% suffered severe adverse events. (Source: PR Presswire)


The successes with the RSHO treatment for our neighbors to the South, came in conjunction with appointment of a new sales manager at HempMeds.

“We are excited to bring Eric onto the HempMeds sales team as the new Sales Manager and we know that he has the talent to continue the positive momentum HempMeds® has in the fast-growing cannabinoid market,” said Medical Marijuana, Inc. Chief Executive Officer Dr. Stuart Titus. “We know that with his impressive sales background he is the right choice to motivate our sales teams and further expand the Company’s goals.” (Source: PR Newswire)

Another MJNA subsidiary, Kannaway held an exclusive Red-Carpet Event in Denver, CO., the following weekend.

There certainly have been numerous events happening at Medical Marijuana, Inc. (OTCMKTS: MJNA) regarding various events with its subsidiaries, but we must remain cautious and remember that before this series of events occurred, MJNA had been on a general downtrend for a considerable period. With that said, the stock seems to have found solid level of support, and chatter on investor message boards is taking on a rather favorable tone. We’ll keep on the case and continue to follow its progress. Stay up to speed with any MJNA breaking developments right here on Street Register by signing up for our 100% free penny stock newsletter. That offer may change as we are contemplating going to a paid membership program. Enter your active email address into the box below and hit Subscribe Now for a limited time!